Zevra Therapeutics (NASDAQ:ZVRA) CEO Neil Mcfarlane Sells 20,000 Shares of Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) CEO Neil Mcfarlane sold 20,000 shares of Zevra Therapeutics stock in a transaction on Monday, October 12th. The shares were sold at an average price of $11.25, for a total value of $225,000.00. Following the sale, the chief executive officer directly owned 417,225 shares of the company’s stock, valued at approximately $4,693,781.25. This trade represents a 4.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA traded down $0.93 during mid-day trading on Tuesday, hitting $10.39. The stock had a trading volume of 1,090,427 shares, compared to its average volume of 1,257,931. The company has a 50 day moving average of $11.54 and a two-hundred day moving average of $11.40. The firm has a market cap of $616.96 million, a PE ratio of 11.29 and a beta of 0.98. Zevra Therapeutics, Inc. has a twelve month low of $8.01 and a twelve month high of $15.03.

Get Zevra Therapeutics alerts:

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. The business had revenue of $39.66 million for the quarter, compared to analysts’ expectations of $33.88 million. Equities research analysts predict that Zevra Therapeutics, Inc. will post 0.72 EPS for the current fiscal year.

Institutional Trading of Zevra Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC acquired a new position in Zevra Therapeutics during the 1st quarter worth approximately $11,184,000. Dimensional Fund Advisors LP grew its stake in shares of Zevra Therapeutics by 259.2% during the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after purchasing an additional 400,336 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in Zevra Therapeutics by 116.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock valued at $5,502,000 after buying an additional 206,543 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Zevra Therapeutics in the second quarter valued at $2,846,000. Finally, Globeflex Capital L P acquired a new stake in Zevra Therapeutics in the second quarter valued at $2,752,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on ZVRA. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Zevra Therapeutics in a report on Wednesday, August 19th. BTIG Research reduced their price objective on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Monday, July 27th. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Finally, Citizens Jmp upped their target price on Zevra Therapeutics from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $27.14.

Read Our Latest Stock Report on Zevra Therapeutics

Zevra Therapeutics Company Profile

(Get Free Report)

Zevra Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.

Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat.

Featured Stories

• Five stocks we like better than Zevra Therapeutics
• A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
• Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
• Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
• Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs

Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.